BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KCNQ2 Cure Alliance - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KCNQ2 Cure Alliance
X-ORIGINAL-URL:https://www.kcnq2cure.org
X-WR-CALDESC:Events for KCNQ2 Cure Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20180311T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20181104T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20190310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20191103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20200308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20201101T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20190724T100000
DTEND;TZID=America/Denver:20190724T110000
DTSTAMP:20260404T182143
CREATED:20190723T015641Z
LAST-MODIFIED:20190723T015641Z
UID:76877-1563962400-1563966000@www.kcnq2cure.org
SUMMARY:A New Clinical Trial in KCNQ2-DEE and Upcoming Related Patient Survey
DESCRIPTION:A New Clinical Trial in KCNQ2-DEE and Upcoming Related Patient Survey \nThe KCNQ2 Cure Alliance has invited Dr. John Millichap\, a Pediatric Epileptologist focused on KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)\, and Dr. Simon Pimstone\, CEO of Xenon Pharmaceuticals\, to participate in this webinar. \nModerated by Caroline Loewy from the KCNQ2 Cure Alliance\, topics will include:\n•	How mutations in the KCNQ2 gene for potassium channels in the brain are responsible for KCNQ2-DEE\n•	What we’ve learned to date from off-label use of Potiga®/Trobalt® as a treatment of pediatric KCNQ2-DEE\n•	Challenges of pediatric clinical trials in rare\, genetic epilepsies\n•	Update on XEN496\, a new pediatric formulation Potiga®/Trobalt® currently in development for KCNQ2-DEE\n•	Upcoming patient surveys and how this information will help shape future clinical trials\n•	Panel discussion\, next steps\, and ways to stay informed! \n————————————————————————-\nDr. Millichap is a Pediatric Epileptologist in the Comprehensive Epilepsy Center\, Ann & Robert H. Lurie Children’s Hospital of Chicago\, and Associate Professor of Pediatrics and Neurology at Northwestern University Feinberg School of Medicine. \nDr. Simon Pimstone is the CEO of Xenon Pharmaceuticals\, a company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders\, including rare central nervous system (CNS) conditions\, with a particular focus on epilepsy.
URL:https://www.kcnq2cure.org/event/a-new-clinical-trial-in-kcnq2-dee-and-upcoming-related-patient-survey/
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR